ReviewNature reviews. Microbiology2018
New opportunities for managing acute and chronic lung infections.
Review in Nature reviews. Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The respiratory microbiota alpha-diversity in chronic lung diseases: first systematic review and meta-analysis.Respiratory research · 2022Pooled it
- Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach.Journal of advanced research · 2026Article
- Limited value of Nanopore adaptive sampling in a long-read metagenomic profiling workflow of clinical sputum samples.BMC medical genomics · 2025Article
- Antimicrobial peptide delivery to lung as peptibody mRNA in anti-inflammatory lipids treats multidrug-resistant bacterial pneumonia.Nature biotechnology · 2025Article
- Microbiota diversity and differences in the respiratory tract of children with pneumonia.Pediatric investigation · 2025Article
- Molecular probes for in vivo optical imaging of immune cells.Nature biomedical engineering · 2025Review
- YouTube and TikTok as sources of information on acute pancreatitis: a content and quality analysis.BMC public health · 2025Article
- From Microbial Ecology to Clinical Challenges: The Respiratory Microbiome's Role in Antibiotic Resistance.Pathogens (Basel, Switzerland) · 2025Review
- Investigation of pure lung microbiota in patients with lung cancer after eliminating upper airway contamination: a prospective cohort study.Journal of thoracic disease · 2024Article
- Review
- Lung-specific supramolecular nanoparticles for efficient delivery of therapeutic proteins and genome editing nucleases.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Does "all disease begin in the gut"? The gut-organ cross talk in the microbiome.Applied microbiology and biotechnology · 2024Review
- Genomic attributes of airway commensal bacteria and mucosa.Communications biology · 2024Article
- Routine Metagenomics Service for ICU Patients with Respiratory Infection.American journal of respiratory and critical care medicine · 2024Article
- Swarming Magnetic FeResearch (Washington, D.C.) · 2024Article
- Harnessing three-dimensional (3D) cell culture models for pulmonary infections: State of the art and future directions.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Metagenomic sequencing reveals swine lung microbial communities and metagenome-assembled genomes associated with lung lesions-a pilot study.International microbiology : the official journal of the Spanish Society for Microbiology · 2023Article
- Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer.International journal of molecular sciences · 2023Review
- Deciphering Microbiota of Acute Upper Respiratory Infections: A Comparative Analysis of PCR and mNGS Methods for Lower Respiratory Trafficking Potential.Advances in respiratory medicine · 2023Article
- Clinical Evaluation of Metagenomic Next-Generation Sequencing and Identification of Risk Factors in Patients with Severe Community-Acquired Pneumonia.Infection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lung diseases caused by microbial infections affect hundreds of millions of children and adults throughout the world. In Western populations, the treatment of lung infections is a primary driver of antibiotic resistance. Traditional therapeutic strategies have been based on the premise that the healthy lung is sterile and that infections grow in a pristine environment. As a consequence, rapid advances in our understanding of the composition of the microbiota of the skin and bowel have not yet been matched by studies of the respiratory tree. The recognition that the lungs are as populated with microorganisms as other mucosal surfaces provides the opportunity to reconsider the mechanisms and management of lung infections. Molecular analyses of the lung microbiota are revealing profound adverse responses to widespread antibiotic use, urbanization and globalization. This Opinion article proposes how technologies and concepts flowing from the Human Microbiome Project can transform the diagnosis and treatment of common lung diseases.
Indexed as
Identifiers
29062070What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.